相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunophenotypic shift in theB-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment inB-lymphoblastic leukemia
Gaurav Chatterjee et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 PatientsKey terms
Prashant R. Tembhare et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2020)
Adult Bone Marrow Three-Dimensional Phenotypic Landscape of B-Cell Differentiation
Claire Carrion et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy
Sindhu Cherian et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Evaluation of New Markers for Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia: CD73 and CD86 Are the Most Relevant New Markers to Increase the Efficacy of MRD Assay
Prashant R. Tembhare et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
Prisca Theunissen et al.
BLOOD (2017)
Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia
Dario Campana et al.
BLOOD (2017)
Principles of Minimal Residual Disease Detection for Hematopoietic Neoplasms by Flow Cytometry
Brent L. Wood
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
Jacques J. M. van Dongen et al.
BLOOD (2015)
Apparent CD19 Expression by Natural Killer Cells: A Potential Confounder for Minimal Residual Disease Detection by Flow Cytometry in B Lymphoblastic Leukemia
Lorinda Soma et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2015)
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
Patricia Stow et al.
BLOOD (2010)
分享论文
